

# Resource Summary Report

Generated by [RRID](#) on Aug 11, 2026

## Cytiva: Biacore X100

RRID:SCR\_025586

Type: Tool

### Proper Citation

Cytiva: Biacore X100 (RRID:SCR\_025586)

### Resource Information

**URL:** <https://www.cytivalifesciences.com/en/us/shop/protein-analysis/spr-label-free-analysis/spr-systems/biacore-x100-p-05730>

**Proper Citation:** Cytiva: Biacore X100 (RRID:SCR\_025586)

**Description:** Automated system for comprehensive, label-free analysis and characterization of biomolecular interactions in real-time. Can be used for applications, including structure function studies, pathway analysis, biomarker discovery and validation, drug target identification and validation, and assay development.

**Synonyms:** Biacore X100

**Resource Type:** instrument resource

**Keywords:** analysis and characterization of biomolecular interactions in real-time, structure function studies, pathway analysis, biomarker discovery and validation, drug target identification and validation, assay development,

**Specification URL:** <https://cdn.cytivalifesciences.com.cn/api/public/content/digi-15563-pdf>, <https://cdn.cytivalifesciences.com/api/public/content/digi-14524-original>,

**Resource Name:** Cytiva: Biacore X100

**Resource ID:** SCR\_025586

**Alternate IDs:** Model\_Number\_Biacore\_X100

**Record Creation Time:** 20240806T053245+0000

**Record Last Update:** 20260808T190727+0000

### Ratings and Alerts

No rating or validation information has been found for Cytiva: Biacore X100.

No alerts have been found for Cytiva: Biacore X100.

---

## Data and Source Information

**Source:** [SciCrunch Registry](#)

---

## Usage and Citation Metrics

We found 2 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [RRID](#) .

Ravazza D, et al. (2026) Quantitative Mass Spectrometry-Based Biodistribution of Monoclonal Antibodies: An Alternative to Radio-Biodistribution. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 13(38), e20265.

Osman ST, et al. (2026) Repurposing SGLT2 and DPP-4 inhibitors for mild cognitive impairment in type 2 diabetes mellitus: Insights from proteomics, target prediction and molecular docking. British journal of pharmacology, 183(10), 2533.